Stevanato Group (STVN) Aperçu de l'action
Stevanato Group S.p.A. se consacre à la conception, à la production et à la distribution de produits et de processus destinés à fournir des solutions aux industries biopharmaceutiques et de soins de santé en Europe, au Moyen-Orient, en Afrique, en Amérique du Nord, en Amérique du Sud et dans la région Asie-Pacifique. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 5/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
STVN ont passé avec succès nos contrôles de risques.
STVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stevanato Group S.p.A. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$19.00 |
| Plus haut sur 52 semaines | US$28.00 |
| Plus bas sur 52 semaines | US$12.89 |
| Bêta | 0.78 |
| Variation sur 1 mois | 2.93% |
| Variation sur 3 mois | 39.30% |
| Variation sur 1 an | -21.97% |
| Variation sur 3 ans | -40.40% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -3.41% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 15
STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power
Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.Seeking Alpha • Jun 11
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Summary Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes. Margin expansion, operational leverage from new facilities, and growth are not well reflected in the current valuation. We reiterate our buy rating. Read the full article on Seeking AlphaRecent updates
Mise à jour du récit • Jun 15
STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power
Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.Seeking Alpha • Jun 11
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Summary Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes. Margin expansion, operational leverage from new facilities, and growth are not well reflected in the current valuation. We reiterate our buy rating. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 01
STVN: Biologics Strength And GLP-1 Exposure Will Balance Execution Risks
Narrative Update Analysts have trimmed their average price targets for Stevanato Group by several dollars per share, generally moving into a $19 to $32 range as updated models reflect Q4 results, revised GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research points to a more cautious tone around Stevanato Group, with several price targets reset into a tighter band even after Q4 results came in ahead of some expectations.Mise à jour du récit • May 08
STVN: Core Biologics Shift Will Support Future Earnings Power Despite Guidance Reset
Narrative Update Analysts have trimmed Stevanato Group's average price target to reflect the recent cuts to $19, $26, $28 and $32, with updated models indicating a fair value estimate of about $24.81. This is based on slightly lower margin assumptions, a modest adjustment to long term growth, a somewhat lower discount rate, and a higher expected future P/E multiple.Mise à jour du récit • Apr 23
STVN: Core Biologics Shift Will Drive Future Earnings Power
Analysts have trimmed their Stevanato Group price targets by several dollars across the Street, now clustering in a $19 to $32 range, as they refresh models after Q4 results and factor in slightly lower long term margin, growth, and P/E assumptions, alongside shifting expectations for GLP-1 and core biologics revenue contributions. Analyst Commentary Recent research updates show analysts marking down their price targets but still drawing a clear line between near term noise and the longer term setup for Stevanato Group, especially around GLP-1 exposure and the broader biologics portfolio.Mise à jour du récit • Apr 09
STVN: Biologics And GLP-1 Exposure Will Support Future Upside Potential
Analysts have trimmed the Stevanato Group fair value estimate from $18.09 to $17.50 after a series of reduced Street price targets, citing updated models post Q4 results, a higher discount rate, slightly softer revenue growth and margin assumptions, and a higher future P/E multiple that still reflects support for the core biologics and GLP-1 exposure. Analyst Commentary Recent Street research has largely centered on resetting expectations after Q4, with several bearish analysts trimming price targets while still recognizing the support from biologics and GLP-1 exposure.
Mise à jour du récit • Mar 26
STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows
Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.Mise à jour du récit • Mar 11
STVN: Biologics Mix Shift And On Body Delivery Partnership Will Support Future Cash Flows
Analysts have trimmed their consolidated price target on Stevanato Group by $4.09 to $32.00. This reflects updated models after Q4 results, slightly lower fair value assumptions, modestly higher discount rates, and more measured expectations for revenue growth, profit margins, and future P/E, even as they continue to highlight strength in GLP-1 and broader biologics demand.Mise à jour du récit • Feb 25
STVN: Large-Volume Self-Administration Partnership Will Support Future Upside Potential
Analysts have trimmed their 12 month price target on Stevanato Group by about $4.90 per share to reflect updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E multiples, citing recent Street research calls that include Jefferies cutting its target by $5.50. Analyst Commentary Bearish analysts are signaling a more cautious stance on Stevanato Group, reflected in reduced 12 month price targets that factor in updated views on fair value, discount rates, revenue growth, profit margins, and future P/E multiples.Mise à jour du récit • Feb 09
STVN: Large Volume On-Body Delivery Partnership Will Support Stronger Future Cash Flows
Analysts have nudged their fair value estimate for Stevanato Group slightly higher to US$36.09, citing small adjustments to discount rate assumptions, revenue growth outlook, profit margin expectations, and a refined future P/E framework. What's in the News Datwyler, LTS Device Technologies and Stevanato Group entered a collaboration focused on large volume subcutaneous drug delivery using on-body administration for larger dose volumes (Key Developments).Article d’analyse • Feb 04
Why We're Not Concerned Yet About Stevanato Group S.p.A.'s (NYSE:STVN) 27% Share Price Plunge
Unfortunately for some shareholders, the Stevanato Group S.p.A. ( NYSE:STVN ) share price has dived 27% in the last...Mise à jour du récit • Jan 26
STVN: Large Volume Drug Delivery Collaboration Will Support Stronger Future Cash Flows
Analysts have nudged their price target for Stevanato Group slightly higher to $36.08 from $36.05, citing updated assumptions for revenue growth, profit margins, and future P/E that modestly adjust their long term valuation. What's in the News Datwyler, LTS Device Technologies and Stevanato Group announced a collaboration focused on large volume subcutaneous drug delivery, targeting more convenient on body administration of larger doses for patients, with a joint platform to be presented at Pharmapack in Paris on January 21 to 22, 2026 (Key Developments).Mise à jour du récit • Jan 11
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts now estimate Stevanato Group's fair value price target at approximately US$36.05, a very small adjustment from about US$36.08. This reflects updated views that combine slightly higher revenue growth expectations with modestly lower profit margin assumptions and a marginally higher future P/E outlook.Article d’analyse • Jan 06
Are Stevanato Group S.p.A. (NYSE:STVN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stevanato Group fair value estimate is US$16.36 Current share...Mise à jour du récit • Dec 27
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts have nudged their price target on Stevanato Group slightly higher to approximately $36.08 per share from about $36.05, citing modestly stronger expectations for revenue growth and profit margins that more than offset a small anticipated decline in the company’s future price to earnings multiple. What's in the News Maintained 2025 revenue guidance, expecting between €1.160 billion and €1.190 billion, signaling confidence in demand and operational execution (Corporate Guidance) Announced a significant expansion of drug delivery system manufacturing capacity in Bad Oeynhausen, Germany, adding over 2,500 square meters of advanced production space to support global pharma and biotech customers (Business Expansions) Invested multi millions in an ISO 8 cleanroom environment equipped for injection molding and automated assembly, aimed at strengthening resilient, Europe based supply chains for partners (Business Expansions) Enhanced the Bad Oeynhausen site to scale production of key devices such as the Aidaptus autoinjector and Alina pen injector platforms, reinforcing the company’s role in patient centric combination products (Business Expansions) Valuation Changes Fair Value Estimate has risen slightly to approximately $36.08 per share from about $36.05.Mise à jour du récit • Dec 12
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Profit Margins
Analysts have modestly trimmed their price target on Stevanato Group to approximately $36.05 from about $36.07, reflecting slightly higher perceived risk via a raised discount rate, which is only partly offset by improved profit margin expectations and a marginally lower forecast valuation multiple. What's in the News Maintained 2025 revenue guidance, with expected revenue in the range of €1.160 billion to €1.190 billion (Corporate guidance) Announced a significant expansion of drug delivery system manufacturing capacity at its Bad Oeynhausen, Germany facility, adding over 2,500 square meters of advanced production space (Business expansion) Invested multiple millions in a new ISO 8 cleanroom, injection molding, and automated assembly operations to support global pharma and biotech partners with resilient European supply chains (Business expansion) Strengthened production capabilities for key platforms, including the Aidaptus autoinjector and Alina pen injector, enhancing its role in patient centric combination products (Business expansion) Valuation Changes Fair Value Estimate: edged down slightly to approximately €36.05 from about €36.07 per share, reflecting a marginally lower intrinsic valuation.Mise à jour du récit • Nov 25
STVN: German Facility Expansion Will Drive Stronger Supply Chain Integration
Analysts have slightly lowered their price target for Stevanato Group, adjusting the fair value from $28.80 to $28.78 based on minor updates to growth and profitability expectations. What's in the News Stevanato Group S.p.A. maintained its revenue guidance for 2025, expecting revenues in the range of €1.160 billion to €1.190 billion (Key Developments).Mise à jour du récit • Nov 11
STVN: Expansion Of German Manufacturing Facility Will Fuel Future Upside
Narrative Update on Stevanato Group Price Target Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.Article d’analyse • Sep 22
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Stevanato Group S.p.A.'s ( NYSE:STVN ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong...Article d’analyse • Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
NYSE:STVN 1 Year Share Price vs Fair Value Explore Stevanato Group's Fair Values from the Community and select yours A...Seeking Alpha • Mar 09
Stevanato: Ramping Syringe Demand, Buy Confirmed
Summary Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war. Stevanato's valuation is supported by sales accelleration and EBITDA growth evolution. Read the full article on Seeking Alpha
Nouveau récit • Nov 20
Engineering Optimization And Capacity Expansion To Unlock Growth Opportunities
Optimizing the Engineering segment and strategic shifts towards ready-to-use systems are expected to drive cost savings, improve margins, and boost productivity.Seeking Alpha • Nov 13
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Summary Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target. Read the full article on Seeking AlphaSeeking Alpha • May 29
Stevanato: Destock Pressures, Long-Term Upside
Summary Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares. Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand. STVN is not trading at a premium compared to its peers. Therefore, we reinstated a buy rating status. Read the full article on Seeking AlphaRendement pour les actionnaires
| STVN | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | 9.4% | 2.1% | 1.6% |
| 1Y | -22.0% | 16.5% | 18.6% |
Rendement vs Industrie: STVN a sous-performé le secteur US Life Sciences qui a rapporté 16.5 % au cours de l'année écoulée.
Rendement vs marché: STVN a sous-performé le marché US qui a rapporté 18.6 % au cours de l'année écoulée.
Volatilité des prix
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 5.6% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: STVN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de STVN ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1949 | 6,010 | Franco Stevanato | www.stevanatogroup.com |
Stevanato Group S.p.A. se consacre à la conception, à la production et à la distribution de produits et de processus destinés à fournir des solutions aux industries biopharmaceutiques et de soins de santé en Europe, au Moyen-Orient, en Afrique, en Amérique du Nord, en Amérique du Sud et dans la région Asie-Pacifique. Elle opère à travers deux segments : Solutions biopharmaceutiques et diagnostiques ; et Ingénierie. La société propose des solutions de confinement des médicaments comprenant des seringues pré-remplissables, des cartouches, des flacons et des ampoules ; des solutions de diagnostic in vitro ; des systèmes d'administration de médicaments, notamment des stylos injecteurs, des auto-injecteurs et des injecteurs portables ; des consommables de laboratoire de diagnostic ; des services de soutien analytique et réglementaire ; des dispositifs médicaux ; des machines d'inspection visuelle pharmaceutique ; des machines d'assemblage et d'emballage ; des machines de transformation du verre ; et des services après-vente, tels que l'optimisation et la conversion de lignes, la formation, la logistique, les pièces de rechange et les services de maintenance.
Stevanato Group S.p.A. Résumé des fondamentaux
| STVN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$5.19b |
| Bénéfices(TTM) | US$161.67m |
| Recettes(TTM) | US$1.38b |
32.1x
Ratio P/E3.8x
Ratio P/SLe site STVN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| STVN compte de résultat (TTM) | |
|---|---|
| Recettes | €1.20b |
| Coût des recettes | €851.68m |
| Marge brute | €351.58m |
| Autres dépenses | €210.23m |
| Les revenus | €141.35m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.52 |
| Marge brute | 29.22% |
| Marge bénéficiaire nette | 11.75% |
| Ratio dettes/capitaux propres | 28.3% |
Quelles ont été les performances à long terme de STVN?
Voir les performances historiques et les comparaisonsDividendes
0.3%
Rendement actuel des dividendes10%
Ratio de distributionLe site STVN verse-t-il des dividendes fiables ?
Voir STVN l'historique des dividendes et les indices de référence| Stevanato Group dates des dividendes | |
|---|---|
| Date ex-dividende | Jun 11 2026 |
| Date de paiement du dividende | Jul 29 2026 |
| Jours jusqu'au dividende Ex | 25 days |
| Jours jusqu'à la date de paiement du dividende | 23 days |
Le site STVN verse-t-il des dividendes fiables ?
Voir STVN l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/06 10:26 |
| Cours de l'action en fin de journée | 2026/07/02 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Stevanato Group S.p.A. est couverte par 19 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Curtis Moiles | BNP Paribas |
| Hugo Solvet | BNP Paribas |
| Michael Ryskin | BofA Global Research |